不同方法治疗内分泌失调性不孕症患者的疗效分析

Effect of letrozole versus clomiphene on endometrial thickness of endocrine disorder infertility

目的 探讨来曲唑与克罗米芬对内分泌失调性不孕症子宫内膜厚度的影响及疗效.方法 随机选取2011年3月至2014年10月本院收治的内分泌失调性不孕症患者80例,依据治疗方法将这些患者分为来曲唑组（n=40）和克罗米芬组（n=40）.对两组患者的子宫内膜厚度及不良反应发生情况进行统计分析.结果 来曲唑组治疗第1～6个月的子宫内膜厚度显著大于克罗米芬组（P＜0.05）,妊娠患者排卵前子宫内膜厚度显著大于克罗米芬组（P＜0.05）,排卵前子宫内膜厚度≥10 mm的发生率为58.8％（10/17）,显著高于克罗米芬组的26.3％（5/19）（P＜0.05）,不良反应发生率为5.0％（2/40）,显著低于克罗米芬组35.0％ （14/40） （P＜0.05）.结论 来曲唑较克罗米芬在内分泌失调性不孕症患者临床治疗中的效果显著,患者的子宫内膜厚度较大,不良反应发生率较低,值得推广.

Objective To investigate the effect of letrozole versus clomiphene on endometrial thickness of endocrine disorder infertility and the efficacies.Methods 80 patients with endocrine disorder infertility treated at our hospital from March,2011 to October,2014 were randomly selected and were divided into a letrozole group （n=40） and a clomiphene group （n=40） according to treatment methods.The endometrial thickness and the incidence of adverse reactions of these two groups were statistically analyzed.Results The endometrial thickness month 1-6 of the treatment of the letrozole group was significantly thicker than that 1 month after treatment of the clomiphene group （P〈0.05）;the endometrial thickness before ovulation of pregnant patients was significantly thicker than that of the clomipheme group （P〈0.05）;the incidence of ≥10 mm endometrial thickness before ovulation and the incidence of adverse reactions were 58.8% （10/17） and 5.0% （2/40） in the letrozole group and were 26.3% （5/19） and 35.0% （14/40） in the clomiphene group （P〈0.05）.Conclusion Compared with clomiphene,letrozole for patients with endocrine disorder infertility can make the patients＆#39; endometrial thickness thicker and decrease the incidence of adverse reaction lower,so it is worth being generalized.